Formestane

Drug Profile

Formestane

Alternative Names: 4-HAD; 4-Hydroxyandrostenedione; 4-OHA; AT 0931; CGP 32349; CRC 8201; CRC-82/01; Formestane IM depot injection; Lentaron

Latest Information Update: 19 Jul 2010

Price : $50

At a glance

  • Originator Novartis
  • Class Androstenes; Antineoplastics; Ketosteroids; Small molecules
  • Mechanism of Action Aromatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Market Withdrawal Breast cancer

Most Recent Events

  • 19 Jul 2010 Development discontinued for Breast cancer during 2001
  • 07 Mar 2003 A study has been added to the Cancer therapeutic trials section
  • 27 Apr 1999 Clinical data have been added to the therapeutic trials, pharmacodynamics and pharmacokinetics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top